Fig. 5

TRPC3 apparent molecular weight (AMW) and Pyr10-induced SPCa inhibition change between WT and DMD^mdx rats in EDL muscle. A Immunoblot of TRPC3 of EDL muscle homogenates from 4 different rats (2 WT: WT-1 and WT-2 and 2 DMD^mdx: DMD^mdx-1 and DMD^mdx-2) of 4.5 months of age. WT and DMD^mdx homogenates were alternated in the different lanes to underline the difference in AMW. B Relation between glycosylation and phosphorylation status and AMW. Immunoblots of TRPC3 of EDL muscle from the same DMD^mdx and WT rats in Control conditions (Control) or after deglycosylation (Deglyco), acetone treatment only (Acetone) and, acetone treatment and dephosphorylation (Dephospho). C AMW of TRPC3 measured in immunoblots for EDL muscle homogenates from 4 WT and 4 DMD^mdx rats. Measures were made for at least two replicates for each rat. Bars represent mean ± values. *: significantly different from WT value, Mann–Whitney test, P < 0.05. D Agarose gel electrophoresis showing RT-PCR amplicons corresponding to the exon 8 to exon 10 of TRPC3 mRNA from EDL muscles of WT and DMD^mdx rats, and pld as a plasmid expressing the full-length rat TRPC3 mRNA isoform. bp: size in base pairs. E: Pyr10-induced SPCa inhibition expressed as fold change of the mean value of SPCa measured in control conditions in WT EDL muscle fibers. Bars represent mean ± values of SPCa measured in n EDL muscle fibers from N WT and DMD^mdx rats aged of 4.5 months (n/N are indicated under brackets) before (filled bars) and after (empty bars) application of Pyr10 compound. *: significantly different from WT value measured in the same conditions, Two-way ANOVA and Fisher post-hoc test, P < 0.05. $: significantly different from mean SPCa value measured in control conditions in the same genotype, Paired Student’s t-test, P < 0.05